ExpreS2ion: Update on progress in Oxford-led malaria vaccine programs
Today, ExpreS2ion provided an update on the progress made during the third quarter across its malaria vaccine programs led by the University of Oxford.
Two ongoing studies have now reached full recruitment status and are moving toward data analysis, while two new studies have begun recruitment, with completion targeted for late 2026 and mid-2027, respectively.
In total, ten Oxford-led malaria vaccine studies using ExpreS2ion’s ExpreS2 platform remain active. Six of these are Phase I trials focused on assessing safety, tolerability, and early immune responses, while four are Phase II trials evaluating the strength and durability of immune responses as well as early efficacy signals.
Further data readouts are expected from late 2025 and into 2026/27.
The company reiterated the potential shareholder value embedded in these malaria projects but also noted that publicly funded studies typically carry lower direct revenue potential. The key value for shareholders remain:
- Licensing opportunities, such as the ongoing term-sheet discussions with Serum Institute of India Pvt. Ltd. (SIIPL), which include malaria candidates.
- Validation of the ExpreS2 platform in human clinical settings.
- Increased visibility of ExpreS2ion’s technology across global health programs.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR agreement. Michael Friis, 12.35, 10/11-2025